Praxis Precision Medicines Inc.
Praxis Precision Medicines Terminates 2024 Sales Agreement and Enters New 2025 Sales Agreement
Summary
Praxis Precision Medicines, Inc. terminated its 2024 Sales Agreement with Jefferies LLC on September 2, 2025, effective immediately, and entered into a new Sales Agreement with TD Securities (USA) LLC on September 5, 2025, for an equity offering program to sell up to $250 million of its common stock through an 'at the market' offering. The 2024 Sales Agreement allowed for the sale of 1,368,176 shares of common stock for approximately $86.2 million in gross proceeds. The new 2025 Sales Agreement includes parameters for the sale of shares and allows TD Cowen to sell shares through various methods. A legal opinion on the validity of the shares to be issued under the 2025 Sales Agreement has been provided by Latham & Watkins LLP.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement